Related Experiment Video

Updated: Aug 6, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Novel agents and targets in managing patients with metastatic prostate cancer

Winston W Tan1

  • 1Department of Hematology/Oncology, Mayo Clinic, Jacksonville, FL 32224, USA. tan.winston@mayo.edu

Cancer Control : Journal of the Moffitt Cancer Center
|August 4, 2006
PubMed
Abstract

Insights

Docetaxel improves survival for metastatic androgen-independent prostate cancer (AIPC). New drug combinations are needed to improve AIPC treatment outcomes beyond current options.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Docetaxel demonstrates improved survival in metastatic androgen-independent prostate cancer (AIPC).
  • Current first-line chemotherapy options for AIPC offer room for improvement.
  • Second-line treatment options for AIPC are varied and debated.

Purpose of the Study:

  • To review chemotherapy drugs for metastatic prostate cancer.
  • To evaluate the mechanism of action and efficacy of these agents.
  • To identify promising treatments for advanced prostate cancer.

Main Methods:

  • Literature review of clinically relevant articles.
  • Focus on chemotherapy drugs for metastatic prostate cancer.
  • Data collected from January 2004 to April 2006.

Main Results:

  • Docetaxel is established as the standard of care for AIPC.
  • Combination therapies with docetaxel show promise.
  • Investigational agents like calcitriol, thalidomide, bevacizumab, satraplatin, vaccines, ixabepilone, and atrasentan exhibit potential.

Conclusions:

  • Docetaxel is recommended for first-line treatment of metastatic AIPC.
  • Current progression-free survival (6 months) necessitates development of more effective treatments.
  • Combination therapies require further investigation in large-scale Phase III trials with survival as the primary endpoint.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...